| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8420676 | CUBIST PHARMS LLC | Oxazolidinone derivatives |
Feb, 2028
(3 years from now) | |
| US7816379 | CUBIST PHARMS LLC | Oxazolidinone derivatives |
Jun, 2028
(4 years from now) | |
| US9624250 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(5 years from now) | |
| US10442829 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(5 years from now) | |
| US8426389 | CUBIST PHARMS LLC | Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Dec, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10065947 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(5 years from now) | |
| US9988406 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(5 years from now) | |
Sivextro is owned by Cubist Pharms Llc.
Sivextro contains Tedizolid Phosphate.
Sivextro has a total of 7 drug patents out of which 0 drug patents have expired.
Sivextro was authorised for market use on 20 June, 2014.
Sivextro is available in tablet;oral, powder;intravenous dosage forms.
Sivextro can be used as method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria, method of treating bacterial infections.
Drug patent challenges can be filed against Sivextro from 21 June, 2023.
The generics of Sivextro are possible to be released after 31 December, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 20, 2024 |
| New Patient Population(NPP) | Jun 19, 2023 |
Drugs and Companies using TEDIZOLID PHOSPHATE ingredient
NCE-1 date: 21 June, 2023
Market Authorisation Date: 20 June, 2014
Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria
Dosage: TABLET;ORAL; POWDER;INTRAVENOUS
SIVEXTRO family patents
